Phase I study of anticolon cancer humanized antibody A33

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1338-1346

  Welt, Sydney ^a,b   Ritter, Gerd ^b   Williams Jr , Clarence ^b   Cohen, Leonard S ^b   John, Mary ^b   Jungbluth, Achim ^b   Richards, Elizabeth A ^b   Old, Lloyd J ^b   Kemeny, Nancy E ^a  

^a Department of Medicine ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; HUMAN ANTIHUMAN ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33; PARACETAMOL; PETHIDINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BIOSENSOR; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOLYSIS; DIARRHEA; DRUG TOLERABILITY; EOSINOPHILIA; ERYTHEMA; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERURICEMIA; HYPOTENSION; IMMUNOGENICITY; KIDNEY FAILURE; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REPRODUCIBILITY; RHINORRHEA; RIGOR; URTICARIA; VOMITING;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MIDDLE AGED; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037390263     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Daghighian, F., Barendswaard, E., Welt, S., Humm, J., Scott, A., Willingham, M. C., McGuffie, E., Old, L. J., and Larson, S. M. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J. Nucl. Med., 37: 1052-1057, 1996.
2. Garin-Chesa, P., Sakamoto, J., Welt, S., Real, F. X., Rettig, W. J., and Old, L. J. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int. J. Oncol., 9: 465-471, 1996.
3. 131I-monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res., 57: 2181-2186, 1997.
4. Barendswaard, E. C., Scott, A. M., Divgi, C. R., Williams, C., Jr., Coplan, K., Riedel, E., Yao, T-J., Gansow, O. A., Finn, R. D., Larson, S. M., Old, L. J., and Welt, S. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int. J. Oncol., 12: 45-53, 1998.
5. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. J. Nucl. Med., 40: 1764-1768, 1999.
6. Deckert, P. M., Jungbluth, A., Montalto, N., Clark, M. A., Finn, R. D., Williams, C., Jr., Richards, E. C., Panageas, K. S., Old, L. J., and Welt, S. Pharmacokinetics and microdistribution of polyethylene glycolmodified humanized A33 antibody targeting colon cancer xenografts. Int. J. Cancer, 87: 382-390, 2000.
7. Ruan, S., O'Donoghue, J. A., Larson, S. M., Finn, R. D., Jungbluth, A., Welt, S., and Humm, J. L. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J. Nucl. Med., 41: 1905-1912, 2000.
8. Barendswaard, E., Humm, J. L., O'Donoghue, J. A., Sgouros, G., Finn, R. D., Scott, A. M., Larson, S. M., and Welt, S. Relative therapeutic efficacy of 1-125- and 1-131-labeled A33 in a human colon xenograft. J. Nucl. Med., 42: 1251-1256, 2001.
9. Welt, S., Divgi, C. R., Kemeny, N., Finn, R. D., Scott, A. M., Graham, M., St. Germain, J., Richards, E. C., Larson, S. M., Oettgen, H. F., and Old, L. J. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 12: 1561-1571, 1994.
10. Welt, S., Scott, A. M., Divgi, C. R., Kemeny, N. E., Finn, R. D., Daghighian, F., St Germain, J., Richards, E. C., Larson, S. M., and Old, L. J. Phase I/II study of iodine 125-labeled antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 14: 1787-1797, 1996.
11. Welt, S., Divgi, C. R., Real, F. X., Yeh, S. D., Garin Chesa, P., Finstad, C. L., Sakamoto, J., Cohen, A., Sigurdson, E. R., Kemeny, N., Carswell, E. A., Oettgen, H. F., and Old, L. J. Quantitative analysis of antibody localization in human metastatic colon cancer: a Phase I study with monoclonal antibody A33. J. Clin. Oncol., 8: 1894-1906, 1990.
12. Catimel, B., Ritter, G., Welt, S., Old, L. J., Cohen, L., Nerrie, M. A., White, S. J., Heath, J. K., Demediuk, B., Domagala, T., Lee, F. T., Scott, A. M., Tu, G. F., Ji, H., Moritz, R. L., Simpson, R. J., Burgess, A. W., and Nice, E. C. Purification and characterization of a novel differentiation marker for normal and transformed colonic epithelium. J. Biol. Chem., 271: 25664-25670, 1996.
13. Heath, J. K., White, S. J., Johnstone, C. N., Catimel, B., Simpson, R. J., Moritz, R. L., Tu, G-F., Ji, H., Whitehead, R. H., Groenen, L. C., Scott, A. M., Ritter, G., Cohen, L., Welt, S., Old, L. J., Nice, E. C., and Burgess, A. W. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. USA, 94: 469-474, 1997.
14. Ji, H., Moritz, R. L., Reid, G. E., Ritter, G., Catimel, B., Nice, E., Heath, J. K., White, S. J., Welt, S., Old, L. J., Burgess, A. W., and Simpson, R. J. Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody. A33. Electrophoresis, 18: 614-621, 1997.
15. Ritter, G., Cohen, L. S., Nice, E. C., Catimel, B., Burgess, A. W., Moritz, R. L., Ji, H., Heath, J. K., White, S. J., Welt, S., Old, L. J., and Simpson, R. J. Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem. Biophys. Res. Commun., 236: 682-686, 1997.
16. Geissler, F., Anderson, S. K., Venkatesan, P., and Press, O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res., 52: 2907-2915, 1992.
17. Shih, L. B., Lu, H. H., Xuan, H., and Goldenberg, D. M. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int. J. Cancer, 56: 538-545, 1994.
18. King, D. J., Antoniw, P., Owens, R. J., Adair, J. R., Haines, A. M. R., Farnsworth, A. P. H., Finney, H., Lawson, A. D. G., Lyons, A., Baker, T. S., Baldock, D., Mackintosh, J., Gofton, C., Yarranton, G. T., McWilliams, W., Shochat, D., Leichner, P. K., Welt, S., Old, L. J., and Mountain, A. Preparation and pre-clinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br. J. Cancer, 72: 1364-1372, 1995.
19. Antoniw, P., Farnsworth, A. P. H., Turner, A., Haines, A. M. R., Mountain, A., Mackintosh, J., Shochat, D., Humm, J., Welt, S., Old, L. J., Yarranton, G. T., and King, D. J. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br. J. Cancer, 74: 513-524, 1996.
20. Catimel, B., Nerrie, M., Scott, A. M., Ritter, G., Welt, S., Old, L. J., Burgess, A. W., and Nice, E. C. Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen using an optical biosensor: a comparison of immobilisation strategies. J. Chromatogr., 776: 15-30, 1997.
21. Ritter, G., Cohen, L. S., Williams, C., Jr., Richards, E. C., Old, L. J., and Welt, S. Serological analysis of human anti-human antibody (HAHA) responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res., 61: 6851-6859, 2001.
22. Burton, D. R., and Woof, J. M. Human antibody effector function. Adv. Immunol., 51: 1-84, 1992.
23. Welt, S., Carswell, E. A., Vogel, C-W., Oettgen, H. F., and Old, L. J. Immune and non-immune effector function of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin. Immunol. Immunopathol., 45: 214-229, 1987.
24. Baselga, J. Clinical trials of single-agent trastuzumab (Herceptin). Semin. Oncol., 27 (Suppl. 9): 20-26, 2000.
25. Cooley, S., Bums, L. J., Repka, T., and Miller, J. S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol., 27: 1533-1541, 1999.
26. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.
27. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
28. Yang, X., Jia, X., Corvalan, J. R., Wang, P., and Davis, C. G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol., 38: 17-23, 2001.
29. Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., and Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res., 59: 1236-1243, 1999.
30. y) antibodies generated against synthetic and natural Ley determinants. Proc. Natl. Acad. Sci. USA, 91: 12957-12961, 1994.
31. Co, M. S., Baker, J., Bednarik, K., Janzek, E., Neruda, W., Mayer, P., Plot, R., Stumper, B., Vasquez, M., Queen, C., and Loibner, H. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. Cancer Res., 56: 1118-1125, 1996.
32. LoBuglio, A. F., Saleh, M. N., Braddock, J. M., Lampkin, T. A., Khor, S. P., Wissel, P. S., and Bigley, J. W. A Phase I trial of humanized anti-EGP40 monoclonal antibody 3622W94. Proc. Am. Soc. Clin. Oncol., 16: 436a, 1997.
33. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer; seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
34. Bindon, C. I., Hale, G., Bruggemann, M., and Waldmann, H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as Clq. J. Exp. Med., 168: 127-142, 1988.
35. Welt, S., Ritter, G., Kemeny, N. E., Jungbluth, A. A., Mahalingam, E., Cohen, L., Iversen, K., Williams, C., and Old, L. J. Phase I study of combination of humanized A33 (huA33) immunotherapy and chemotherapy in patients with advanced colorectal cancer. Am. Assoc. Clin. Oncol., 20: 276a, 2001.
36. Segerling, M., Ohanian, S. H., and Borsos, T. Chemotherapeutic drugs increase killing of tumor cells by antibody and complement. Science (Wash. DC), 188: 55-57, 1975.
37. Schlager, S. I., and Ohanian, S. H. Correlation between lipid synthesis in tumor cells and their sensitivity to humoral immune attack. Science (Wash. DC), 197: 773-776, 1977.
38. Pegram, M. D., Lopez, A., Konecny, G., and Slamon, D. J. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol., 27 (Suppl. 11): 21-25, 2000.
39. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
40. Wilson, W. H. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin. Oncol., 27 (Suppl. 12): 30-36, 2000.
41. Ravetch, J. V., and Lanier, L. L. Immune inhibitory receptors. Science (Wash. DC), 290: 84-89, 2000.